Back to Browse Journals » Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy » Volume 3

Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes

Authors Karen Barnard, Mary Elizabeth Cox, Jennifer B Green

Published Date October 2010 Volume 2010:3 Pages 363—372

DOI http://dx.doi.org/10.2147/DMSO.S10195

Published 27 October 2010

Karen Barnard1,2, Mary Elizabeth Cox1, Jennifer B Green1,2
1Department of Medicine, Division of Endocrinology, Diabetes, Metabolism and Nutrition, Duke University Medical Center, Durham, NC, USA; 2Department of Medicine, Division of Endocrinology, Durham Veterans Affairs Medical Center, Durham, NC, USA

Abstract: Adequate glycemic control in type 2 diabetes remains a difficult but achievable goal. The development of new classes of glucose-lowering medications, including in particular the incretin-based therapies, provides an opportunity to utilize combinations of medications which target multiple physiologic abnormalities in type 2 diabetes. Complementary combination therapy with sitagliptin–metformin lowers glucose via enhancement of insulin secretion, suppression of glucagon secretion, and insulin sensitization. Use of this combination in diabetes management will provide a greater degree of glycosylated hemoglobin-lowering than that seen with the use of either drug as monotherapy, is unlikely to cause significant hypoglycemia, and is generally associated with weight loss. The effectiveness, tolerability, and potential cost savings associated with the use of sitagliptin–metformin combination therapy make this an attractive option in diabetes management. The possible beneficial effects of this therapy on beta cell function, as well as its cardiovascular impact, remain inadequately explored but are of significant interest.

Keywords: diabetes mellitus, sitagliptin, dipeptidyl peptidase-4, combination therapy

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other articles by this author:

Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy

Mary Elizabeth Cox, Jennifer Rowell, Leonor Corsino, et al

Drug, Healthcare and Patient Safety 2010, 2:7-19

Published Date: 28 January 2010

New combination treatments in the management of diabetes: focus on sitagliptin – metformin

Jennifer Green, Mark Feinglos

Vascular Health and Risk Management 2008, 4:743-751

Published Date: 4 September 2008

Readers of this article also read: